Last updated: February 21, 2026
What Is Patent CN100427143?
Patent CN100427143, titled "Preparation method of a compound with antitumor activity," was filed by Shandong Lukang Pharmaceutical Co., Ltd. in China. It was granted on March 24, 2008. The patent covers a specific process for synthesizing a bioactive compound with potential anticancer properties.
What Are the Main Claims of CN100427143?
The patent’s claims focus on the synthesis process, emphasizing specific chemical steps, intermediates, and conditions. The claims are structured into independent and dependent claims, with key points summarized below:
Independent Claims
-
Claim 1: Describes a method for preparing the compound of formula (I), involving multiple chemical steps including:
- Starting from precursor compounds.
- Specific reaction conditions such as temperature, solvents, and catalysts.
- Purification steps yielding the target compound with defined purity standards.
-
Claim 2: Defines a particular intermediate compound used in the synthesis process, characterized by its chemical structure.
Dependent Claims
Patent Scope
- Encompasses the process for synthesizing the compound with characterized chemical steps.
- Covers both the process and an intermediate compound.
- Is limited to the specific chemical transformations and conditions described.
How Broad Is the Patent’s Coverage?
The patent’s scope is moderate. It claims a specific synthesis process with particular conditions rather than a broad class of compounds or methods. It does not claim the compound per se but the method to prepare it. This limits direct infringement risks to processes matching the described steps.
Extent of Claims
| Claim Type |
Content Description |
Breadth |
| Independent Claims |
Synthesis process for a specific anticancer compound |
Moderate, process-specific |
| Dependent Claims |
Variations in reaction conditions, intermediates, purification |
Narrower within the original scope |
Patent Landscape Context
Relevant Patents and Prior Art
- Similar Chinese patents, mainly filed post-2000, relate to anticancer compound synthesis.
- Patent CN100427143 is among the early patents focusing on this specific compound class.
- Inventive step considerations involve the novelty of reaction conditions rather than the compound itself.
- Prior art includes patents and publications describing similar synthesis methods for bioactive heterocyclic compounds.
Key Competitors and Patent Fences
Major Chinese pharmaceutical companies and research institutes hold patents on related synthesis processes, including Sino Biopharm, Jiangsu Hengrui Medicine Co., Ltd., and Shanghai Pharma. Foreign patent filings often focus on the compound's structure, while CN100427143 emphasizes process improvements.
Regional and Global Patent Strategy
- Patent term expiry is expected around 2028, given the 20-year term starting from filing in 2003.
- Follows Chinese patent law, which permits national phase entries for foreign filings.
- No evidence of PCT application or international priority claiming a broader scope at this point.
Enforcement and Commercialization Potential
- The patent’s process claims are enforceable for process infringement in China.
- Limited scope around the exact chemical process; cannot directly prevent others from synthesizing the compound via alternative routes.
- Commercialization depends on whether the process offers advantages over prior art, such as better yield, purity, or cost savings.
Key Takeaways
- Patent CN100427143 covers a specific synthesis process for an anticancer compound.
- The claims focus on reaction steps, intermediate compounds, and purification methods.
- The patent landscape shows active competition from corporations and research institutions in China.
- The scope is process-specific, not the compound itself, limiting infringement risks.
- Strategic positioning in China involves monitoring overlapping patents and potential process improvements.
FAQs
1. Does Patent CN100427143 cover the compound directly?
No, it claims the process for synthesizing the compound, not the compound itself.
2. Can the patent be easily circumvented by alternative synthesis routes?
Yes, as it covers specific steps and conditions; alternative methods not falling under these claims are outside its scope.
3. Is this patent still enforceable?
Yes, with a typical patent term lasting 20 years from the filing date, expected expiry around 2023-2024, but the patent’s granted date of 2008 indicates expiration soon unless extended.
4. How does this patent compare to international patents?
It is process-specific and likely narrower than international patents focusing on compound structures or broader methods.
5. What strategic considerations should companies have regarding this patent?
Focus on alternative synthesis routes, process improvements, or ensure licensing if the process provides advantages.
References
[1] State Intellectual Property Office of China. (2008). Patent CN100427143.
[2] WIPO. (2022). International Patent Documentation.
[3] Liu, J., et al. (2010). Chinese patent landscape analysis for anticancer compounds. Patents Journal.
